Open-Label Trial of Neoadjuvant Imatinib Mesylate (Glivec) in Patients With Locally Advanced Malignant Gastrointestinal Stromal Tumors (GIST) Expressing c-Kit or Platelet-Derived Growth Factor Receptor-Alpha.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 07 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jan 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 09 Sep 2005 New trial record.